Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment

In this episode presented by AnaptysBio, Jennifer Smith-Parker speaks to Dr. Joe Murray, professor of medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, and Department of Immunology, The Mayo Clinic; Marilyn Gellar, CEO, The Celiac Disease Foundation; and Dr. Paul Lizzul, chief medical officer, AnaptysBio, about the unmet need for effective treatments for celiac disease, the limitations of the gluten-free diet and the development of ANB033, a first-in-class CD122 antagonist designed to modulate IL-2/IL-15 signaling.HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsDr. Joe Murray, Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine and Department of Immunology, The Mayo ClinicMarilyn Geller, CEO, Celiac Disease FoundationDr. Paul Lizzul, Chief Medical Officer, AnaptysBio Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

There are no comments yet.

Please log in to write the first comment.